Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of axicabtagene ciloleucel (Yikaida) in adults with r/r large B-cell lymphoma after ineffective first-line immunochemotherapy
CTR20240335Phase 4Active
- Sponsor
- Fosun Kairos
- Start
- May 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 4 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), Epstein-Barr virus-positive diffuse large B-cell lymphoma, Epstein-Barr virus-positive mucocutaneous ulcer (EBV-MCU), diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI), sponsored by Fosun Kairos. Started May 2025; status: active.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary cutaneous diffuse large B-cell lymphoma (PCDLBCL)Epstein-Barr virus-positive diffuse large B-cell lymphomaEpstein-Barr virus-positive mucocutaneous ulcer (EBV-MCU)diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI)
Beyond the preview
Go deeper on CTR20240335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240335.